EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its s...
Freenome plans to complete all modules of its premarket approval submission in mid-2025....
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer sc...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer sc...